Recombinant
RabMAb

Recombinant Anti-CD38 antibody [EPR4106] (ab108403)

Publishing research using ab108403? Please let us know so that we can cite the reference in this datasheet.

ab108403 has been referenced in 6 publications.

  • Huang YH  et al. Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma. Cancers (Basel) 11:N/A (2019). PubMed: 30791634
  • Li Y  et al. Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. Oncoimmunology 6:e1356147 (2017). PubMed: 29147607
  • Esch MB  et al. Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow. Lab Chip 15:2269-77 (2015). PubMed: 25857666
  • Ceroni F  et al. A deletion involving CD38 and BST1 results in a fusion transcript in a patient with autism and asthma. Autism Res 7:254-63 (2014). PubMed: 24634087
  • Chini CC  et al. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. Clin Cancer Res 20:120-30 (2014). WB ; Human . PubMed: 24025713
  • Kobayashi M  et al. Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis. World J Gastroenterol 20:3597-608 (2014). IHC-P ; Human . PubMed: 24707143

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up